1. Home
  2. MRCC vs GANX Comparison

MRCC vs GANX Comparison

Compare MRCC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$6.56

Market Cap

133.2M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
GANX
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.2M
159.2M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
MRCC
GANX
Price
$6.56
$2.19
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$8.00
$8.00
AVG Volume (30 Days)
135.4K
2.1M
Earning Date
02-27-2026
11-12-2025
Dividend Yield
10.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,742,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.86
$1.41
52 Week High
$8.85
$4.34

Technical Indicators

Market Signals
Indicator
MRCC
GANX
Relative Strength Index (RSI) 56.44 36.83
Support Level $6.08 $2.04
Resistance Level $6.80 $3.29
Average True Range (ATR) 0.21 0.32
MACD 0.03 -0.13
Stochastic Oscillator 92.31 13.12

Price Performance

Historical Comparison
MRCC
GANX

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: